Cancer Immunotherapy

Local Immunotherapy Reduces Prostate Cancer Growth

Published in Cancer Weekly, October 18th, 1999

Local intratumor immunotherapy with interleukin-2 (IL-2) reduces tumor growth in a rat prostate cancer model.

S.H. Hautmann and colleagues from the University of Miami, Florida, evaluated the effectiveness and toxicity of local continuous immunotherapy for prostatic cancer. Their results were reported in the journal Anticancer Research ("Local Intratumor Immunotherapy of Prostate Cancer with Interleukin-2 Reduces Tumor Growth," Anticancer Research, 1999;19:2661-2663).

The researchers treated 60 juvenile male Copenhagen rats with Dunning adenocarcinoma of the prostate. The rats were subcutaneously implanted with tumor cells into both flanks. After...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry